Not All Prostate-Specific Membrane Antigen Imaging Agents Are Created Equal: Diagnostic Accuracy of Ga-68 PSMA-11 PET/CT for Initial and Recurrent Prostate Cancer

By Purysko AS, Abreu AL, Lin DW, Punnen S

This is an open access article under the terms of the License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. This review article is sponsored by Telix Pharmaceuticals.


Positron emission tomography (PET) radiotracers that target prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed in prostate cancer (PCa) cells, are highly sensitive and specific for the detection of metastatic PCa. The radioactive PET imaging agent Ga-68 PSMA-11 has demonstrated higher PCa detection rates compared with conventional imaging techniques, leading to its increased use in the diagnosis of PCa. In this review of literature published between February 2015 and December 2022, of 76 studies in >5000 men with PCa, we examined the accuracy and clinical use of Ga-68 PSMA-11 PET for the initial staging of PCa, assessment of biochemical recurrence (BCR), and how this technique may affect the clinical management of PCa. The majority of studies evaluating Ga-68 PSMA-11 PET for primary staging and for BCR demonstrated a sensitivity ≥80% and a specificity ≥90%. Ga-68 PSMA-11 PET led to a change in clinical management in 19% to 52% and 16% to 75% of patients with primary PCa and BCR, respectively. Variations in diagnostic accuracy parameters were observed among studies but were anticipated given differences in patient characteristics (eg, PSA, lesion sizes) and study designs. No serious adverse events were noted with Ga-68 PSMA-11 PET. Overall, Ga-68 PSMA-11 offers high sensitivity, is well tolerated, and can result in clinical management changes for patients with primary PCa and BCR.


Prostate cancer (PCa) is diagnosed in approximately 1.3 million men each year and represents the second most common cancer in men worldwide.1 The American Cancer Society estimated 288,300 new cases and 34,700 deaths from PCa in the United States in 2023.2 The 5-year survival rate is 99% for patients with localized/regional PCa, but only 32% for patients with distant metastasis.3

PCa recurrence, defined as an increase in prostate-specific antigen (PSA) levels after treatment, occurs in up to 90% of cases, depending on initial risk categorization and definitive therapy. Biochemical recurrence (BCR) is defined as a PSA level of 0.2 ng/mL followed by a confirmatory PSA level of ≥0.2 ng/mL after radical prostatectomy (RP) and nadir PSA level + 2.0 ng/mL after radiotherapy.4 Patients with preoperative PSA levels of <2.6 ng/mL, 2.6 to 10 ng/mL, and >10 ng/mL are expected to have recurrence rates of 10%, 20%, and 50%, respectively.5 Approximately 40% to 90% of patients with high-risk features develop BCR following prostatectomy3,6 and 30% to 50% experience BCR following radiation therapy.7 However, multinomial nomograms based on other clinical factors, such as Gleason grade group and clinical stage, provide more accurate estimates of BCR.8

PCa is diagnosed via biopsy of the prostate, with imaging playing an important role in its diagnosis and management. However, staging for higher-risk disease is often performed using conventional imaging with computed tomography (CT) and bone scintigraphy, which have suboptimal sensitivities for detecting metastases for initial staging.9 CT and Tc-99m methyl diphosphonate bone scintigraphy are routinely used to stage disease in patients with confirmed PCa and to assess suspected PCa recurrence. These methods, however, have limited sensitivity in detecting metastatic disease, particularly when patients have smaller lesions and lower PSA levels.10

Recent advances in diagnostic imaging have overcome these limitations. Positron emission tomography (PET) radiotracers that target prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed in PCa cells, are highly sensitive and specific, with a high detection rate for metastatic PCa lesions. Thus, PSMA radiotracers are recommended for PET imaging of PCa without the prerequisite use of conventional imaging.11 Ga-68 PSMA-11 is one such radioactive PET imaging agent that has demonstrated higher PCa detection rates compared with conventional imaging techniques, leading to its increased use along with other PET imaging agents.12 Figure 1 shows an example of a pelvic node in the setting of BCR that was positive on Ga-68 PSMA-11 PET/CT, but negative on CT.

Ga-68, a β+ emitting radionuclide, is one of the most common radioisotopes used in PET scans worldwide.13 PET imaging using Ga-68 PSMA-1114 was approved by the US Food and Drug Administration (FDA) as the first PSMA-targeted imaging agent on December 1, 2020, followed by approval of a kit for the preparation of Ga-68 PSMA-11 (TLX591-CDx) on December 17, 2021 for widespread commercial use.15

Ga-68 PSMA-11 is approved for the detection of suspected metastasis in the initial staging of patients with PCa and the identification of suspected PCa BCR after treatment.14 Ga-68 PSMA-11 is also approved in the US to identify and select patients who are candidates for FDA-approved PSMA-directed radioligand therapy. A recent study also reported a significant effect of Ga-68 PSMA-11 on the staging and management of PCa across all relevant clinical scenarios, including patients with PSA below the threshold for BCR, those with known metastatic or advanced castration-resistant disease, and those who have undergone primary treatments other than surgery or radiotherapy.16

Herein we review the available literature to assess the sensitivity and specificity of Ga-68 PSMA-11 PET for PCa imaging along with its safety and clinical use for PCa management. Literature searches were conducted using PubMed to identify published studies relevant to the use of Ga-68 PSMA-11 PET for the detection and staging of primary PCa and to detect and localize BCR. Search terms included “primary prostate cancer,” “prostate cancer,” “PSMA,” “PET,” “staging,” and “biochemically recurrent.” The initial search was limited to studies published in English from February 2015 to November 2021. A second search was conducted to identify articles from November 2021 to December 2022 using the same search terms. Overall, 75 studies in >5000 men with PCa were identified that examined the accuracy and clinical use of Ga-68 PSMA-11 PET for the initial staging of PCa and assessing BCR (Figure 2).

Primary staging of PCa using Ga-68 PSMA-11

Table 1 summarizes the results of studies that assessed Ga-68 PSMA-11 for the primary staging of PCa. The majority of studies demonstrated a sensitivity ≥80% and a specificity ≥90%. Sensitivity of Ga-68 PSMA-11 ranged from 30% to 100% for detecting PCa, 24% to 100% for detecting cancer in the lymph nodes, and 84% to 100% for detecting bone metastases; its specificity ranged from 45% to 100% for the prostate, 82% to 100% for the lymph nodes, and 92% to 100% for bone metastases. The positive predictive value (PPV) ranged from 60% to 100%, and the negative predictive value (NPV) ranged from 25% to 100% in both localized and metastatic PCa, with the majority of these studies reporting values in the upper range.12,17-64Additionally, a prospective study highlighted the prognostic value of 68-Ga PSMA-11 PET/CT versus conventional imaging with 99mTc bone scintigraphy and CT for primary staging in 247 high-risk patients with PCa treated with RP. Primary staging with 68-Ga PSMA-11 PET/CT resulted in a significantly lower biochemical recurrence risk after RP vs conventional imaging, likely due to improved selection of patients for RP.65

Table 1

View a pdf of Table 1

Initial PCa detection and T staging

In a study evaluating 144 patients (median PSA 8.6 ng/mL), Ga-68 PSMA-11 PET/CT was compared with multiparametric MRI (mpMRI) for the detection of localized PCa, with biopsy histopathology used as a reference standard for the full cohort and RP specimen used as the reference standard in a subset of patients.24 Ga-68 PSMA-11 showed a higher sensitivity for detecting index lesions (90.1%) compared with mpMRI (83.1%), although this difference was not significant (p = 0.267). The median size of index tumor foci missed by mpMRI (1.66 cm3; interquartile range [IQR], 0.79–2.53 cm3) was significantly larger than that of tumor foci missed by Ga-68 PSMA-11 PET/CT (0.72 cm3; IQR, 0.36–1.0 cm3; p = 0.034). Among the 136 patients who had clinically significant PCa detected on biopsy (defined as Gleason score of ≥7), Ga-68 PSMA-11 was significantly more sensitive than mpMRI in detecting cancer within the prostate (95% vs. 86%, respectively;p = 0.017), but both imaging methods had high specificities (93% vs. 94%, respectively). Overall, Ga-68 PSMA-11 PET/CT detected significantly more cancer than mpMRI for the entire cohort based on both biopsy (p</i >= 0.004) and RP histopathology (p = 0.020).

In another study evaluating 54 patients with PCa with a median PSA level of 13.30 ng/mL, Ga-68 PSMA-11 PET/CT and PET/MRI were more sensitive in detecting extracapsular extension (PET/CT, 78%; PET/MRI, 83%) compared with mpMRI (mpMRI, 54%;p < 0.05).22 Ga-68 PSMA-11 PET/CT and PET/MRI also tended to have higher sensitivity for detecting seminal vesicle invasion (75%) compared with mpMRI (67%), but the difference was not statistically significant. The specificity, PPV, and NPV were also not significantly different among these modalities. The timing of biopsy (before vs after Ga-68 PSMA-617 PET/CT) did not seem to affect the outcomes of Ga-68 PSMA PET/CT imaging in high-risk patients with PCa.66

Initial PCa N and M staging

In the multicenter proPSMA study, 302 patients were randomly assigned to undergo Ga-68 PSMA-11 PET/CT or conventional imaging (combination of CT and bone scan) for the evaluation of pelvic nodal and distant metastatic disease.37 Patients were included in the study if they had untreated, biopsy-proven PCa; were being considered for curative-intent treatment; and had ≥1 high-risk criterion (PSA ≥20 ng/mL, International Society of Uropathology grade group 3–5, or clinical stage ≥T3). In these patients, Ga-68 PSMA-11 PET/CT demonstrated a 27% (95% confidence interval [CI], 23%–31%; p < 0.0001) absolute greater area under the curve (AUC) for accuracy than conventional imaging (92% vs. 65%, respectively). Conventional imaging, when compared with Ga-68 PSMA-11 PET/CT, had lower sensitivity (38% vs. 85%) and specificity (91% vs. 98%).

In another multicenter trial evaluating 764 patients, Ga-68 PSMA-11 PET/CT or PET/MRI was assessed for its accuracy in detecting pelvic nodal metastases compared with histopathology at the time of RP and pelvic lymph node dissection.63 Patients were included if they had histopathology-proven PCa, were planning to undergo RP, and had intermediate- to high-risk disease (PSA level >10 ng/mL, T-state ≥T2b, Gleason score >6, or other risk factors). The sensitivity and specificity of Ga-68 PSMA-11 PET for pelvic nodal metastases were 40% and 95%, respectively. The sensitivities from this study were lower than the 59% weighted sensitivity reported in a systematic review, although the sensitivities in the systematic review did range from 23% to 100%.67 This large variance in sensitivity and specificity for Ga-68 PSMA-11 across studies is likely explained by differences in study design such as the reference standard used, whether data were collected prospectively or retrospectively, and whether patients were recruited consecutively or nonconsecutively.

Effect of Ga-68 PSMA-11 PET On the initial management of PCa

Six studies (n = 493) reported a change in clinical management with Ga-68 PSMA-11 PET in 19% to 52% of patients with primary PCa.22,35,37,42,60,68 Hofman and colleagues37 reported a significant change in treatment plan in 28% of patients undergoing Ga-68 PSMA-11 PET/CT compared with 15% of patients undergoing conventional imaging (p = 0.0076). Similarly, Wong and colleagues68 evaluated the effect of Ga-68 PSMA-11 PET on disease staging in 131 patients with biopsy-proven PCa. Ga-68 PSMA-11 PET led to a change in PCa stage in 28% of patients, with disease being upstaged in 13% of patients and downstaged in 15% of patients (p < 0.001) when compared with the stage assigned using conventional imaging. These findings suggest that Ga-68 PSMA-11 has the potential to provide more accurate staging for metastatic disease, thereby allowing for more risk-appropriate management through the selection of local vs systemic management. Patients may, therefore, receive more appropriate treatment, although the effects of these changes on cancer-specific and overall survival are yet to be determined.

Detection of BCR

Table 2 summarizes studies that evaluated Ga-68 PSMA-11 PET to assess BCR. The majority of studies demonstrate a sensitivity ≥80% and a specificity ≥90%. Sensitivity values ranged from 64% to 99% for the prostate, 72% to 100% for the lymph nodes, and one study reported a sensitivity of 83% for bone metastases. Specificity values ranged from 31% to 100% for the prostate, 50% to 100% for the lymph nodes, and one study reported a specificity of 92% for bone metastases.28,33,53,69-83 The large variance in sensitivity and specificity can be explained by varying factors across studies, such as areas examined (prostate vs lymph nodes) and the reference standard used (Table 2).

Table 2

View a pdf of Table 2

In comparison with conventional imaging, Ga-68 PSMA-11 PET/CT has higher sensitivity, specificity, and accuracy for detecting local recurrence and lymph node metastases, as well as higher detection rates in patients with low PSA levels (≤0.5 ng/mL). In a study of patients who had BCR after definitive PCa treatment with RP (n = 24), radiotherapy (n = 117), or combined treatment (n = 47), patients underwent Ga-68 PSMA-11 PET/CT for the detection of PCa recurrence, with either histologic examination of biopsy sections or 12 months of clinical and imaging follow-up used as the reference standard.74 Ga-68 PSMA-11 PET/CT was found to have a sensitivity of 99% and a specificity of 100% for detecting PCa recurrence. Receiver operating characteristic analysis yielded an ideal PSA cutoff value of >0.65 ng/mL (AUC = 0.964; 95% CI, 0.736–1.000; p < 0.0001), which was associated with a sensitivity of 93% and a specificity of 100% for detecting PCa recurrence with Ga-68 PSMA-11 PET/CT. In patients with lower PSA values (0 to <0.5 ng/ mL), the detection rate was 54.2%.

In a study evaluating 66 patients (median PSA 0.23 ng/mL), Ga-68 PSMA-11 PET/MRI was 55% effective in detecting BCR after RP at low PSA levels (≤0.5 ng/mL), including in patients who had previously undergone or were currently undergoing androgen deprivation therapy (ADT).84 Subgroup analysis of patients with a very low (0 to 0.2 ng/mL) and low PSA (0.2 to 0.5 ng/mL) demonstrated detection rates of 39% and 65%, respectively. Ga-68 PSMA-11 PET/MRI also detected PSMA-positive lesions outside a standard radiotherapy target volume in 39% of patients.

Another study evaluated the accuracy of Ga-68 PSMA-11 PET in detecting lymph node metastases in 65 patients with BCR after RP who were scheduled to undergo salvage lymph node dissection.69 The salvage lymph node dissection templates included lymph nodes from the right and left pelvis, presacral region, and retroperitoneal region. The median diameter of lymph nodes detected on Ga-68 PSMA-11 PET was 7.2 mm (IQR, 5.3–9 mm), whereas the median diameter of false-negative lymph nodes was 3.4 mm (IQR, 2.1–5.4 mm; p = 0.01). Diagnostic accuracy was 99% in the left pelvic region and 95% in the right pelvic, presacral, and retroperitoneal regions. Specificity values were >96% in all regions; sensitivity values were >90% in all but the retroperitoneal region (73%), perhaps because of less dissection of the retroperitoneum during salvage lymph node dissection.

In a study comparing the accuracy of Ga-68 PSMA-11 PET/CT with that of 18F-fluciclovine (a PET radiotracer) PET/CT in detecting BCR after RP in 50 patients, Ga-68 PSMA-11 had a significantly higher detection rate than 18F-fluciclovine (56% vs. 26%, respectively;p = 0.0026).70 Detection rates were significantly higher for Ga-68 PSMA-11 compared with 18F-fluciclovine in the pelvic lymph nodes (30% vs. 8%, respectively;p = 0.0034) and in extrapelvic lesions (16% vs. 0%, respectively;p = 0.0078). Among the 15 patients in whom lesions were verified by histopathology/biopsy, both 18F-fluciclovine and Ga-68 PSMA-11 had PPVs of 100%. Another retrospective analysis of 37 patients with relapsed PCa showed a significantly higher lesion detection rate with Ga-68 PSMA-11 PET/ CT versus standard 18F-fluoromethylcholine PET/CT, especially in patients with low PSA levels.85

Finally, in a pilot study of 14 patients with BCR after RP, 43% of the patients had positive PET scans, including 36% with positive

Ga-68 PSMA-11 scans and 29% with positive 18F-PSMA-1007 scans.86 No additional lesions were identified in the prostate fossa by 18F-PSMA-1007 in comparison to Ga-68 PSMA-11. In a study of 102 patients with BCR, 18F-PSMA-1007 was found to have a significantly higher incidence of PSMA-expressing lesions of benign origin than Ga-68 PSMA-11 (245 vs. 52, respectively).87 Furthermore, the maximum standardized uptake value of these benign lesions was significantly higher (p < 0.0001) for 18F-PSMA-1007, indicating a potentially higher source of false positives with this agent than with Ga-68 PSMA-11.

Effect of Ga-68 PSMA-11 PET On the Management of BCR

Ten studies (n = 1697) reported a change in clinical management with Ga-68 PSMA-11 imaging in 16% to 75% of patients with BCR.71,73,81,82,88-93 In a study of 294 patients, a change in clinical management occurred in 68% of patients, and Ga-68 PSMA-11 PET/CT affected this change in 86% of these patients.73 Treatment modifications guided by Ga-68 PSMA-11 PET/CT were considered effective in 89% of patients; modifications not guided by Ga-68 PSMA-11 PET/CT were considered effective in 61% of patients (p < 0.001). Among patients with BCR following primary curative PCa treatment, delayed imaging with Ga-68 PSMA-11 PET/CT generally led to significantly better uptake and improved contrast, ultimately leading to a change in clinical management for 16% of patients.91 Moreover, in a study of high-risk patients with PCa, primary staging with Ga-68 PSMA-11 PET/CT reduced BCR versus conventional imaging techniques (H = 0.58;p = 0.004).91 Another multicenter prospective trial from 15 countries in 1004 patients with PCa with BCR demonstrated that Ga-68 PSMA-11 PET/CT positivity correlated with Gleason score and PSA level at time of PET scan, PSA doubling time, and radiotherapy as primary treatment. Moreover, treatment modification occurred in 57% of PCa patients with BCR based on the outcomes of Ga-68 PSMA-11 PET/CT imaging.88

Safety Profile of Ga-68 PSMA-11

Ga-68 PSMA-11 is a well-tolerated imaging agent. Five studies (n = 880) reported on the safety of Ga-68 PSMA-11 and found no patients experienced serious adverse events, 18 patients reported experiencing mild adverse events (dizziness, nausea, constipation, diarrhea, headache), and one patient reported a fall after imaging that he attributed to furosemide injection, although there were no associated vital sign changes.12,26,60,72,76 Hofman and colleagues37 also reported a substantially lower radiation exposure with Ga-68 PSMA-11 PET/CT (8.4 mSv) compared with conventional imaging (combination of CT and bone scan) (19.2 mSv;p < 0.001).

Health Economics and Outcomes Research

The cost-effectiveness of Ga-68 PSMA-11 in comparison with conventional imaging has been examined by multiple groups showing that Ga-68 PSMA-11 reduced overall costs because of its increased accuracy in staging, which can obviate the need for unnecessary and costly therapies. In an exploratory analysis evaluating 30 patients over 10 years in Australia, a strategy using Ga-68 PSMA-11 PET/

MRI had an average cost of $39,426 and produced an average of 7.48 years of survival, whereas a strategy involving conventional imaging (bone scan and MRI) had an average cost of $44,667 and produced an average of 7.41 years of survival.94 When the duration of the model was reduced to 5 years, the use of Ga-68 PSMA-11 PET/MRI resulted in cost savings of $3,278 and 0.018 more life-years than conventional imaging. In a cost-effectiveness analysis of the proPSMA study, Ga-68 PSMA-11 PET/CT was found to have a lower estimated cost per scan than the combination of CT and bone scan ($886 vs $1040, respectively).95 In an intention-to-treat analysis evaluating 83 patients with BCR after RP with or without previous radiotherapy, the percentage of patients receiving appropriate curative radio- therapy instead of palliative ADT was 100% with Ga-68 PSMA-11 PET/CT, 74% with C-11 choline PET/CT, and 33% with CT. A retrospective analysis of 244 patients undergoing PSMA PET/CT for recurrent PCa showed that imaging with Ga-68 PSMA-11 was cost-effective compared with 18F-PSMA-1007.96 Outcomes research data are yet to be reported from studies in the United States.


Although Ga-68 PSMA-11 is mainly used for PET imaging of PCa, other 18F ligands are increasingly becoming available. The US FDA recently approved another PSMA-targeted drug, piflufolastat F-18, for imaging of PCa.97 Similar results were observed with the two agents in other studies in patients with recurrent PCa.92,98,99 In a head-to-head comparison in 16 patients with intermediate/high-risk PCa, Ga-68 PSMA-11 and 18F-PSMA-1007 PET/CT showed similar performance in identifying dominant prostate lesions.100 Another study comparing the 18F-PSMA-1007 PET/CT with Ga-68 PSMA-11 PET/CT in 40 treatment-naïve intermediate/high-risk PCa patients showed comparable detection of primary and metastatic lesions.101

However, defluorination of 18F radiotracers may influence the accuracy of lesion detection in bones due to unspecified bone uptake,102 which can alter the choice of treatment and subsequently affect the quality of life of patients.103 Several recent studies have highlighted that 18F radiotracers are likely to lead to misdiagnosis of bone lesions, with one study reporting nearly 6 times more unspecified bone uptake seen on 18F-PSMA-1007 than with Ga-68 PSMA-11 PET imaging.87,96,104-109 A retrospective analysis of data from 10 patients with PCa who underwent PET-guided biopsy to confirm observations of indeterminate bone lesions on 18F-PSMA-1007 PET/ CT imaging demonstrated that 91% (10/11) of the bone lesions were not metastatic and showed no signs of PSMA expression.110

Another study of 243 patients with high-risk or recurrent PCa reported 98 of 267 bone lesions (37%) in 48 (20%) patients with 18F-DCFPyL PET/CT imaging were indeterminate. Of these indeterminate bone lesions, 37 of 98 (38%) were confirmed benign, 42 of 98 (43%) were malignant, and 19 of 98 (19%) remained equivocal at the lesion level. At the patient level, 24 of 48 (50%) had a benign lesion, 11 of 48 (23%) had a malignant lesion, and 13 of 48 (27%) had equivocal findings.103

A retrospective matched-pair comparison of 18F-rhPSMA-7 with 68-Ga PSMA-11 PET/CT in patients with primary or recurrent PCa showed a higher incidence of benign tumors among PSMA-positive lesions reported with18F-rhPSMA-7 versus 68-Ga PSMA-11 (67% [379/566] vs 35% [100/289]).111

In addition, a study of 283 patients who had 68-Ga PSMA-11 PET and 409 patients who had 18F-PSMA-1007 PET due to BCR showed that 18F-PSMA-1007 PET resulted in a significantly higher rate of nonspecific bone uptake compared with 68-Ga PSMA-11 PET (p < 0.001); however, the rate of bone metastases was not significantly different.109

The updated joint European Association of Nuclear Medicine (EANM) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) procedure guidelines for PCa imaging also note non-specific bone uptake with 18F-rhPSMA-7.3.112 18F PET imaging may also lead to higher interobserver variability, as demonstrated by a retrospective study of 584 patients with newly diagnosed PCa. Significantly increased interobserver variability was observed with 18F-PSMA-1007 for bone metastases versus 18F-DCFPyL and Ga-68 PSMA-11 (p = 0.001 and p = 0.03, respectively), and for overall agreement and locoregional lymph node metastases versus 18F-DCFPyL (p < 0.001 and p = 0.01, respectively).113

Guidelines for PSMA imaging

The updated National Comprehensive Cancer Network guidelines now include guidance regarding the use of Ga-68 PSMA-11.114 The guidelines state that, because of the increased sensitivity and specificity of PSMA PET tracers for detecting micrometastatic disease at initial staging and in cases of BCR, conventional imaging is no longer considered a necessary prerequisite to PSMA PET, and PSMA PET/CT or PSMA PET/MRI can serve as an equally effective or more effective first-line imaging tool for these patients.114 The updated joint EANM and SNMMI procedure guidelines for PCa imaging also include the use of Ga-68 PSMA-11 PET/CT and recommend combining PSMA-PET/CT with multiparametric MRI for guiding biopsy for confirmation of PCa.112 Recently,the Society of Nuclear Medicine and Molecular Imaging, American College of Nuclear Medicine, American Urological Association, Australia and New Zealand Society of Nuclear Medicine, American Society of Clinical Oncology, EANM, and the American College of Physicians worked collaboratively to develop appropriate use criteria for PSMA PET imaging (Table 3).115 In addition, the EANM criteria, PROMISE criteria, and PSMA-RADS have also been published to streamline the interpretation of PSMA PET imaging.116


Ga-68 PSMA-11 PET/CT is effective in the initial staging and detection of PCa BCR and has advantages over MRI in the initial local staging of PCa, mainly detection of extraprostatic disease in initial staging and BCR and at low PSA levels (≤0.5 ng/mL); potential for leading to a change in radiotherapy target planning84; and cost-effectiveness while reducing the amount of radiation exposure to the patient.94 Bone lesions are easier to interpret on Ga-68 PSMA-11 compared to 18F-based radiotracer imaging.87,104,111,112 Ga-68 PSMA-11 is well tolerated, further supporting its potential as the imaging agent of choice in PCa.

Ga-68 PSMA-11 has also been used for confirming primary or recurrent PCa in several studies, demonstrating its diagnostic value in clinical practice. Ga-68 PSMA-11 PET/CT was used in combination with MRI to triage patients for biopsy during initial diagnosis and improved NPV for ruling out clinically significant PCa, thereby reducing the number of unnecessary biopsies.117 In addition, Ga-68 PSMA-11 PET/CT was useful for guiding metastasis-directed radiotherapy in patients with oligometastatic PCa recurrence, delaying the need for ADT and potentially prolonging BCR-free survival.118

In a study of patients with metastatic castration-resistant PCa, Ga-68 PSMA-11 PET provided reliable parameters that could be used to predict response to systemic therapies.119 68-Ga PSMA-11 was also used for confirmation of metastatic castration-resistant PCa and identification of appropriate patients for PSMA-based radioligand therapy in the phase 3 VISION trial,120 and is approved in the US for patient selection for PSMA-directed radioligand therapy. Finally, Ga-68 PSMA-11 PET/CT may also be useful in determining appropriate candidates for RP, as the technique has high PPV and specificity for identifying lymph node metastases and local recurrence.121

The main limitation of this review is the heterogeneity of the included studies (varying sample sizes, patients being grouped by differing PSA ranges). Variations in reported diagnostic accuracy parameters were seen as anticipated given differences in patient characteristics (eg, PSA, lesion sizes) and study designs. Also, additional studies are needed to determine the effects of Ga-68 PSMA-11 on cost.

In summary, Ga-68 PSMA-11 PET has a favorable safety profile that affords high accuracy for PCa initial staging and the detection of PCa BCR. Although more studies are needed, its use frequently leads to changes in treatment that may positively affect patient outcomes. With increased access, the use of Ga-68 PSMA-11 is expected to expand and include additional applications.

Purysko AS, Abreu AL, Lin DW, Punnen S. (Mar 05, 2024). Not All Prostate-Specific Membrane Antigen Imaging Agents Are Created Equal: Diagnostic Accuracy of Ga-68 PSMA-11 PET/CT for Ini. Appl Radiol. 2024; 53(2):22-35.
© Anderson Publishing, Ltd. 2024 All rights reserved. Reproduction in whole or part without express written permission Is strictly prohibited.